Market Place
Sourcing Support
Ipsen And Day One Partner On Tovorafenib For Childhood Brain Tumor
25 Jul 2024 //
GLOBENEWSWIRE
Ipsen Secures Ex-US Rights To Day One`s Pediatric Cancer Med For $111M
25 Jul 2024 //
FIERCE PHARMA
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
06 May 2024 //
GLOBENEWSWIRE
Pedia Brain Tumor Fdn Celebrates OJEMDA™ Approval for Pedia Brain Tumor
29 Apr 2024 //
GLOBENEWSWIRE
XOMA Earns $9M As FDA Approves Day One`s Tovorafenib For pLGG
25 Apr 2024 //
GLOBENEWSWIRE
Day One drug for common childhood brain tumor approved by FDA
24 Apr 2024 //
FDA
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval
23 Apr 2024 //
PRESS RELAESE
Day One`s Tovorafenib Gets FDA Approval For Pediatric pLGG
23 Apr 2024 //
GLOBENEWSWIRE
XOMA Earns $5M Milestone Upon Acceptance of Day One™s Tovorafenib NDA for pLGG
31 Oct 2023 //
GLOBENEWSWIRE
Day One Announces FDA Acceptance of NDA for Tovorafenib in pLGG
30 Oct 2023 //
GLOBENEWSWIRE
Day One Announces Updated FIREFLY-1 Data for Tovorafenib
11 Sep 2023 //
GLOBENEWSWIRE
Day One Announces TovorafenibData and Abstracts to be Presented at ASCO
25 May 2023 //
GLOBENEWSWIRE
Good day for Day One as pediatric brain tumor drug proves worth
09 Jan 2023 //
FIERCE BIOTECH
Day One Announces Data from Phase 2 FIREFLY-1 Trial for Tovorafenib
08 Jan 2023 //
GLOBENEWSWIRE
Fennec Pharmaceuticals Announces Commercial Availability of PEDMARK®
17 Oct 2022 //
GLOBENEWSWIRE
Day One Announces Cooperative R&D Agreement with NCI of Tovorafenib
17 Oct 2022 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.